Chong Kun Dang Pharmaceutical Corp.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Drug: ImotunDrug: Placebo
- First Posted Date
- 2012-12-28
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 287
- Registration Number
- NCT01756937
- Locations
- 🇰🇷
Hallym Universicy Sacred heart Hospital, Anyang, Korea, Republic of
🇰🇷Dong-A university Hospital, Busan, Korea, Republic of
🇰🇷Yeungnam university medical center, Daegu, Korea, Republic of
Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2012-12-27
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 238
- Registration Number
- NCT01756430
- Locations
- 🇰🇷
The Hanyang Universitiy Guri Hospital, Guri-si, Gyeonggi-do, Korea, Republic of
Efficacy and Safety Study of Tacrobell to Treat Rheumatoid Arthritis
- First Posted Date
- 2012-12-11
- Last Posted Date
- 2015-08-11
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 111
- Registration Number
- NCT01746680
- Locations
- 🇰🇷
Kyung Hee University Hospital, Seoul, Korea, Republic of
The Study to Evaluate Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Drug: Imotun capsuleDrug: Imotun capsule placebo
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 234
- Registration Number
- NCT01743287
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju, Chungcheonbuk-do, Korea, Republic of
🇰🇷Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷Kyungpook National University Hospital, Daegu, Korea, Republic of
Pharmacokinetics Study of CKD-11101 and NESP After SC Administration in Health Male Volunteers
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 34
- Registration Number
- NCT01685671
- Locations
- 🇰🇷
Seoul national university hospital, Seoul, Korea, Republic of
Pharmacokinetics Study of CKD-11101 and NESP After IV Administration in Health Male Volunteers
- First Posted Date
- 2012-09-13
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 31
- Registration Number
- NCT01684605
- Locations
- 🇰🇷
Seoul national university hospital, Seoul, Korea, Republic of
To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure
- Conditions
- HypertensionCongestive Heart Failure
- Interventions
- Drug: Candemore tablet
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2015-09-24
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 169
- Registration Number
- NCT01682564
- Locations
- 🇰🇷
Inje university pusan hospital, Busan, Busanjin-gu Gaegum-dong, Korea, Republic of
🇰🇷Gyeongsang national university hospital, Jinju, Chiram-dong, Korea, Republic of
🇰🇷Daegu fatima hospital, Daegu, Dong-gu Sinam-dong, Korea, Republic of
Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2012-08-13
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 60
- Registration Number
- NCT01663038
- Locations
- 🇰🇷
Inje University Pusan Paik Hospital, Pusan, Korea, Republic of
Efficacy and Safety of CKD-828 to Stage 2 Hypertension
- Conditions
- Hypertension
- Interventions
- Drug: CKD-828 2.5/40mgDrug: CKD-828 5/40mgDrug: CKD-828 5/80mg
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 103
- Registration Number
- NCT01634295
- Locations
- 🇰🇷
Seoul national university Bundang Hospital, Bundang-gu, Gyeonggi-do, Korea, Republic of
Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial
- First Posted Date
- 2012-06-28
- Last Posted Date
- 2016-09-22
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 141
- Registration Number
- NCT01630018
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Seoul Metropolitan, Korea, Republic of